Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma - Salwender, Hans; Bertsch, Uta; Benner, Axel; Raab, Marc-Steffen; Hillengaß, Jens; Hose, Dirk; Huhn, Stefanie; Hundemer, Michael; Jauch, Anna; Seidel-Glätzer, Andrea; Goldschmidt, Hartmut (BMC cancer, 2019)
Gesehen am 08.07.2019